Wyeth Nutritionals: Pfizer’s New MVP, Or Benchwarmer?
This article was originally published in The Tan Sheet
Executive Summary
Wyeth Nutrition could boost Pfizer's revenue outside the U.S. and buffer some upcoming patent losses in its prescription roster through the pending $68 billion deal
You may also be interested in...
Pfizer To House Consumer, Nutritional Divisions In Diversified Businesses Unit
Pfizer will appoint Wyeth's consumer health president to manage its new Diversified Businesses group, which will include consumer, nutritional and animal health, as part of a reorganization following the companies' planned merger
P&G Pharma Sale Could Bring $1 Billion To Feed Consumer Business
A sale of Procter & Gamble's pharma business could fetch about $1 billion, according to an estimate by one analyst. That represents cash P&G could reinvest in its core business areas, beauty and consumer health care, at a time when the recession is impacting growth and the credit crisis is forcing some retailers to cut inventories to conserve cash
Bristol’s Nutritionals Business Spins Out; IPO Well-Received By Investors
Mead Johnson Nutrition offering breaks health care IPO drought.